Efficacy and safety of SGLT-2i in overweight/obese, non-diabetic individuals: a meta-analysis of randomized controlled trials

被引:5
|
作者
Shi, Yetan [1 ]
Si, Yuexiu [2 ]
Fu, Rongrong [3 ]
Zhang, Mengting [1 ]
Jiang, Ke [1 ]
Dai, Wei [1 ]
Shen, Jingyi [1 ]
Li, Xiangyuan [1 ]
Yuan, Yuan [4 ]
机构
[1] Zhejiang Chinese Med Univ, Clin Med Coll 2, Hangzhou, Zhejiang, Peoples R China
[2] Zhejiang Chinese Med Univ, Sch Basic Med Sci, Hangzhou, Zhejiang, Peoples R China
[3] Zhejiang Chinese Med Univ, Clin Med Coll 1, Hangzhou, Zhejiang, Peoples R China
[4] Univ Chinese Acad Sci, HwaMei Hosp, Dept Gen Surg, Northwest St 41, Ningbo 315010, Zhejiang, Peoples R China
关键词
SGLT-2i; overweight; obese; weight reduction; non-diabetic; meta-analysis; OBESITY; WEIGHT; CANAGLIFLOZIN; INHIBITORS; IMPACT;
D O I
10.5603/EP.a2021.0102
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Sodium-glucose cotransporter 2 inhibitor (SGLT-2i) has been shown to decrease blood glucose levels in type 2 diabetes mellitus (T2DM) patients and potentially yield additional benefits in weight loss. This meta-analysis aimed to investigate the efficacy and safety of giving SGLT-2i to overweight/obese, non-diabetic individuals. Material and methods: The search was underpinned by PubMed, Cochrane Central Register of Controlled Trials, Web of Science, and Springer to identify English-language papers on randomized controlled trials (RCfs) on the use of SGLT-2i in overweight/obese, nondiabetic individuals published in and before March 2021, to study its effectiveness and safety. Results were evaluated by weighted mean difference (WMD), standardized mean difference (SMD), risk ratio (RR), and 95% confidence interval (CI). Results: We reviewed 13 papers and compared the SGLT-2i group with the control group (other drugs and placebo) and found that SGLT-2i reduced weight (WMD = -1.33, p = 0.002) and waist circumference (WMD = -1.94, p = 0.03) in overweight/obese, non-diabetic individuals. The use of SGLT-2i is more effective than other interventions in terms of weight loss >= 5% (RR = 2.04, p < 0.001), but not in terms of weight loss >= 10% (RR = 1.133, p = 0.22). In addition, there were no significant changes in other metabolic parameters, like fasting plasma glucose (FPG), lipids, blood pressure, etc. SGLT-2i increased the risk of infections in urinary tract (RR = 1.91, p = 0.009) and reproductive system (RR= 4.09, p < 0.001). Conclusions: SGLT-2i is a promising candidate to reduce weight and waist circumference to a limited extent in overweight/obese, non-diabetic individuals. Generally, it is safe and effective. However, it potentially increased the risk of urogenital infections, which cannot be ignored.
引用
收藏
页码:71 / 80
页数:10
相关论文
共 50 条
  • [1] Safety and efficacy of SGLT2 inhibitors in diabetic and non-diabetic heart failure patients, a meta-analysis of randomized controlled trials
    Awad, A. K.
    Hasan, M. Tarek
    Shih, M.
    Attia, A. N.
    Aboeldahab, H.
    Bendary, M.
    Bendary, A.
    [J]. EUROPEAN HEART JOURNAL, 2022, 43 : 941 - 941
  • [2] Efficacy of Liraglutide in Non-Diabetic Obese Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Barboza, Joshuan J.
    Huaman, Mariella R.
    Melgar, Beatriz
    Diaz-Arocutipa, Carlos
    Valenzuela-Rodriguez, German
    Hernandez, Adrian, V
    [J]. JOURNAL OF CLINICAL MEDICINE, 2022, 11 (11)
  • [3] SGLT-2i and Risk of Malignancy in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials
    Shi, Nanjing
    Shi, Yetan
    Xu, Jingsi
    Si, Yuexiu
    Yang, Tong
    Zhang, Mengting
    Ng, Derry Minyao
    Li, Xiangyuan
    Xie, Fei
    [J]. FRONTIERS IN PUBLIC HEALTH, 2021, 9
  • [4] The efficacy and safety of liraglutide in the obese, non-diabetic individuals: a systematic review and meta-analysis
    Zhang, Pei
    Liu, Yu
    Ren, Yuan
    Bai, Jie
    Zhang, Guangzhen
    Cui, Yuanshan
    [J]. AFRICAN HEALTH SCIENCES, 2019, 19 (03) : 2591 - 2599
  • [5] Efficacy and safety of Contrave in overweight and obese adults: a meta-analysis and narrative review of randomized controlled trials
    Yue, Xing
    Hu, Rong
    Liu, Shiping
    Zhou, Zhiguang
    [J]. DIABETES-METABOLISM RESEARCH AND REVIEWS, 2015, 31 : 71 - 72
  • [6] Efficacy and safety of subcutaneous semaglutide in adults with overweight or obese: a subgroup meta-analysis of randomized controlled trials
    Zhang, Rui
    Hou, Qin-chuan
    Li, Bing-hong
    Deng, Ling
    Yang, Yu-mei
    Li, Ting-xin
    Yao, Xiao-qin
    Yang, Liang-liang
    Lin, Xi-long
    Liao, Yi-qian
    Wang, Lin
    Liu, Yu-ping
    Tan, Jing
    Wan, Zheng-wei
    Shuai, Ping
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [7] EFFICACY OF PROBIOTICS INTERVENTION ON OBESE INDIVIDUALS: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
    Zhu, Wenyi
    Zhang, Jingwan
    Huang, Wenli
    Lu, Wenqi
    Xu, Zhilu
    Zhang, Lin
    Chan, Francis K.
    Wu, William K.
    Ng, Siew C.
    [J]. GASTROENTEROLOGY, 2022, 162 (07) : S1103 - S1104
  • [8] Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials
    Nalisa, David Lubasi
    Cuboia, Nelson
    Dyab, Eman
    Jackson, Idongesit Linus
    Felix, Habimana Jean
    Shoki, Pantaleon
    Mubiana, Mary
    Oyedeji-Amusa, Mariam
    Azevedo, Luis
    Jiang, Hongwei
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2024, 15
  • [9] The Effects of Acarbose on Non-Diabetic Overweight and Obese Patients: A Meta-Analysis
    Ai-Qing Yu
    Jiong Le
    Wen-Tao Huang
    Bin Li
    Hui-Xin Liang
    Qun Wang
    Yu-Ting Liu
    Charlotte-Aimee Young
    Mei-Ying Zhang
    Shu-Lan Qin
    [J]. Advances in Therapy, 2021, 38 : 1275 - 1289
  • [10] Relationship Between SGLT-2i and Ocular Diseases in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials
    Zhou, Bin
    Shi, Yetan
    Fu, Rongrong
    Ni, Haixiang
    Gu, Lihu
    Si, Yuexiu
    Zhang, Mengting
    Jiang, Ke
    Shen, Jingyi
    Li, Xiangyuan
    Sun, Xing
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2022, 13